PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Venook, Alan P.
TI  - CALGB/SWOG 80405 Results Provide Treatment Options for mCRC
DP  - 2014 Aug 01
TA  - MD Conference Express
PG  - 17--18
VI  - 14
IP  - 14
4099  - http://mdc.sagepub.com/content/14/14/17.short
4100  - http://mdc.sagepub.com/content/14/14/17.full
AB  - The results of the CALGB/SWOG Phase 3 trial [NCT00265850; Venook AP et al. J Clin Oncol 2014] reveal similar outcomes with FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) or FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) chemotherapy combined with cetuximab or bevacizumab as a first-line treatment for select patients with KRAS wild-type metastatic colorectal cancer (mCRC). The similarities mean that patients have treatment choices and can now opt to start treatment with the regimen that they most prefer.